- Home
- UAMY vs ACIU Comparison
UAMY vs ACIU Comparison
Compare UAMY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- ACIU
- Stock Information
- Founded
- UAMY 1968
- ACIU 2003
- Country
- UAMY United States
- ACIU Switzerland
- Employees
- UAMY N/A
- ACIU N/A
- Industry
- UAMY Metal Fabrications
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- ACIU Health Care
- Exchange
- UAMY Nasdaq
- ACIU Nasdaq
- Market Cap
- UAMY 251.9M
- ACIU 247.4M
- IPO Year
- UAMY N/A
- ACIU 2016
- Fundamental
- Price
- UAMY $3.20
- ACIU $1.48
- Analyst Decision
- UAMY Strong Buy
- ACIU Strong Buy
- Analyst Count
- UAMY 3
- ACIU 2
- Target Price
- UAMY $2.20
- ACIU $12.00
- AVG Volume (30 Days)
- UAMY 4.8M
- ACIU 194.4K
- Earning Date
- UAMY 05-13-2025
- ACIU 05-12-2025
- Dividend Yield
- UAMY N/A
- ACIU N/A
- EPS Growth
- UAMY N/A
- ACIU N/A
- EPS
- UAMY N/A
- ACIU N/A
- Revenue
- UAMY $14,937,962.00
- ACIU $30,136,397.00
- Revenue This Year
- UAMY $178.78
- ACIU N/A
- Revenue Next Year
- UAMY $433.71
- ACIU $676.94
- P/E Ratio
- UAMY N/A
- ACIU N/A
- Revenue Growth
- UAMY 71.84
- ACIU 84.51
- 52 Week Low
- UAMY $0.21
- ACIU $1.43
- 52 Week High
- UAMY $3.60
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- UAMY 69.96
- ACIU 24.24
- Support Level
- UAMY $1.69
- ACIU $1.48
- Resistance Level
- UAMY $3.60
- ACIU $1.62
- Average True Range (ATR)
- UAMY 0.31
- ACIU 0.12
- MACD
- UAMY 0.11
- ACIU -0.00
- Stochastic Oscillator
- UAMY 79.06
- ACIU 9.43
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.